Skip to content
Peptigraph home

Mazdutide Phase 3 trial (NCT05606913)

Efficacy and Safety of IBI362 Versus Dulaglutide as add-on to Metformin and/or SGLT2 Inhibitor or TZD in Subjects With Type 2 Diabetes (DREAMS-2)

Registry record checked

At a glance

Phase
Phase 3
Status
Completed
Enrolment
731
actual
Start
6 Jan 2023 (actual)
Primary completion
26 Jan 2024 (actual)
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Design

Arms and doses

NCT05606913 study arms
ArmTypeInterventionsDescription
IBI362 6.0mgExperimentalDrug: IBI362①2mg, SC, once a week\* 4weeks; ②4mg, SC, once a week\* 4weeks;③6mg, SC, once a week\* 20weeks.
dulaglutideExperimentalDrug: dulaglutide1.5mg, SC, once a week\* 28weeks
IBI362 4.0mgExperimentalDrug: IBI3622mg, SC, once a week\* 4weeks; ②4mg, SC, once a week\* 24weeks.
Endpoints

Primary endpoint

NCT05606913 primary outcomes
MeasureTime frame
HbA1c change from baseline at week 28Baseline, 28 weeks
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT05606913 secondary outcomes
MeasureTime frame
percent change from baseline in body weighBaseline, 28 weeks
Proportion of subjects with HbA1c <7.0% and weight loss ≥5% from baselineBaseline, 28 weeks
Change from baseline in HbA1c (superiority)Baseline, 28 weeks
Proportion of subjects with HbA1c <7.0%Baseline, 28 weeks
Safety,Incidence and severity of adverse events and correlation with study drug;Baseline to 32weeks
Time to peak plasma concentration (Tmax)Baseline to 28weeks
Time to peak plasma concentration (Cmax)Baseline to 28weeks
area under curve (AUC)Baseline to 28weeks
volume distribution (V)Baseline to 28weeks
half-life (half-life, T1/2Baseline to 28weeks
clearance rate (clearance, CL)Baseline to 28weeks
To assess changes in PD parameters fasting insulin at different time points before and after administration.Baseline to 28weeks
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
Not stated
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

Sources

  1. 1Efficacy and Safety of IBI362 Versus Dulaglutide as add-on to Metformin and/or SGLT2 Inhibitor or TZD in Subjects With Type 2 Diabetes (DREAMS-2)ClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.